Literature DB >> 8437017

The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

K M Bushby1, D Gardner-Medwin, L V Nicholson, M A Johnson, I D Haggerty, N J Cleghorn, J B Harris, S S Bhattacharya.   

Abstract

We have correlated a detailed clinical assessment of 67 patients with proven Becker muscular dystrophy with the results from genetic and protein analyses. There was an overall deletion frequency of 80%, rising to 92.6% in the large group of patients defined on clinical grounds as being of "typically" mild severity. The deletions in this group were all clustered in the region of the gene between exons 45 and 59; the most common deletion was of exons 45-47 and all but one started at exon 45. No similar deletions were seen in the patients with more severe disease, in whom the diverse genetic defects included a duplication and a very large deletion. Dystrophin patterns in the "typical" group were also very characteristic, and in both groups were as predicted from the genetic defect, the size of deletions being inversely proportional to the size of the protein produced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437017     DOI: 10.1007/bf00858726

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Molecular deletion patterns in Duchenne and Becker type muscular dystrophy.

Authors:  S Liechti-Gallati; M Koenig; L M Kunkel; D Frey; E Boltshauser; V Schneider; S Braga; H Moser
Journal:  Hum Genet       Date:  1989-03       Impact factor: 4.132

2.  Analysis of molecular deletions with cDNA probes in patients with Duchenne and Becker muscular dystrophies.

Authors:  H Gilgenkrantz; J Chelly; M Lambert; D Récan; J C Barbot; G J van Ommen; J C Kaplan
Journal:  Genomics       Date:  1989-10       Impact factor: 5.736

3.  Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons.

Authors:  H G Lidov; T J Byers; S C Watkins; L M Kunkel
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

4.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

5.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

6.  Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody.

Authors:  L V Nicholson; K Davison; G Falkous; C Harwood; E O'Donnell; C R Slater; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

7.  Dystrophin or a "related protein" in Duchenne muscular dystrophy?

Authors:  L V Nicholson; M A Johnson; K Davison; E O'Donnell; G Falkous; M Barron; J B Harris
Journal:  Acta Neurol Scand       Date:  1992-07       Impact factor: 3.209

8.  Genetic abnormalities in Duchenne and Becker dystrophies: clinical correlations.

Authors:  R Medori; M H Brooke; R H Waterston
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

9.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

10.  Improved diagnosis of Becker muscular dystrophy by dystrophin testing.

Authors:  E P Hoffman; L M Kunkel; C Angelini; A Clarke; M Johnson; J B Harris
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

View more
  33 in total

Review 1.  Genetic and clinical correlations of Xp21 muscular dystrophy.

Authors:  K M Bushby
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy.

Authors:  Gyula Acsadi; Steven A Moore; Angélique Chéron; Olivier Delalande; Lindsey Bennett; William Kupsky; Mohammad El-Baba; Elisabeth Le Rumeur; Jean-François Hubert
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

3.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

4.  DMD mutation spectrum analysis in 613 Chinese patients with dystrophinopathy.

Authors:  Ruolan Guo; Guosheng Zhu; Huimin Zhu; Ruiyu Ma; Ying Peng; Desheng Liang; Lingqian Wu
Journal:  J Hum Genet       Date:  2015-05-14       Impact factor: 3.172

Review 5.  Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.

Authors:  Elisabeth Le Rumeur
Journal:  Bosn J Basic Med Sci       Date:  2015-07-20       Impact factor: 3.363

6.  Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Famke Aeffner; Dinesh S Bangari; Torrie A Crabbs; Stacey Fossey; Shayne C Gad; Wanda M Haschek; Jessica S Hoane; Kyathanahalli Janardhan; Ramesh C Kovi; Gail Pearse; Lyn M Wancket; Erin M Quist
Journal:  Toxicol Pathol       Date:  2017-11-07       Impact factor: 1.902

7.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

10.  Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy.

Authors:  Peter J Taylor; Grant A Betts; Sarah Maroulis; Christian Gilissen; Robyn L Pedersen; David R Mowat; Heather M Johnston; Michael F Buckley
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.